Press Releases
Qlucore Recognised by Strategic Innovation Programme for MedTech
22 August 2023 -- Lund, Sweden -- Qlucore, listed on Nasdaq First North and a developer of visualisation-based software for research-focused data analysis and precision diagnostics, has received a grant of SEK 200,000 from innovation agency Vinnova through the strategic innovation programme Medtech4Health. The programme's mission is to implement more medical technology solutions in healthcare for the benefit of patients. The project funded by Medtech4Health aims to enhance Qlucore Diagnostics' ability to protect patient data and ensure data security.
Qlucore Diagnostics is planned to be launched in 2025 as a CE-marked in vitro diagnostic medical device. This means that Qlucore Diagnostics will be authorised for clinical use in hospital laboratories.
22 August 2023 -- Lund, Sweden -- Qlucore, listed on Nasdaq First North and a developer of visualisation-based software for research-focused data analysis and precision diagnostics, has received a grant of SEK 200,000 from innovation agency Vinnova through the strategic innovation programme Medtech4Health. The programme's mission is to implement more medical technology solutions in healthcare for the benefit of patients. The project funded by Medtech4Health aims to enhance Qlucore Diagnostics' ability to protect patient data and ensure data security.
Qlucore Diagnostics is planned to be launched in 2025 as a CE-marked in vitro diagnostic medical device. This means that Qlucore Diagnostics will be authorised for clinical use in hospital laboratories.
"Dividing cancer types into various subgroups provides personalised cancer treatment. This could result in more effective treatment and, in some cases, spare patients from demanding treatments with severe side effects”, says Carl-Johan Ivarsson, CEO of Qlucore and continues:
“We are pleased that Medtech4Health recognises the potential of Qlucore Diagnostics in healthcare, enabling more precise cancer treatment for cancer patients.”
The Qlucore Insights software, designed for research and enabling early testing and evaluation, is already available on the market. Currently, four models are being tested; two for different types of leukemia, one for lung cancer, and one for bladder cancer. Through these classification models, cancer types can be divided into several subgroups, leading to improved information.
Medtech4Health works to implement more medical technology ideas and solutions in healthcare for the benefit of patients. Through collaboration with healthcare providers, academia and the industry, value is created for patients and the medical technology sector is strengthened. Medtech4Health is funded by the Swedish government through the innovation agency Vinnova, the Swedish Energy Agency, the Swedish Research Council for Sustainable Development (Formas), and the programme's participating partners.
Visit: www.medtech4health.se
About Qlucore
Qlucore is a leading provider of new generation intuitive bioinformatics software for research and precision and companion diagnostics. Qlucore’s mission is to make it easier to analyse the huge amounts of complex data generated by innovations in the fields of genomics and proteomics by providing powerful visualisation-based bioinformatics data analysis tools for research and precision diagnostics. Qlucore Omics Explorer software is a easy to use bioinformatics software for research in the life science, plant- and biotech industries, as well as in academia. Qlucore Diagnostics and Qlucore Insights are software platforms with built in AI-based machine learning for multi-omics companion and precision diagnostics. Qlucore was founded in 2007 in Lund, Sweden and has customers in about 25 countries around the world, with sales offices in Europe and North America and distribution in several countries in Asia. Qlucore is listed on the Nasdaq First North Growth market.
Visit: www.qlucore.com
“We are pleased that Medtech4Health recognises the potential of Qlucore Diagnostics in healthcare, enabling more precise cancer treatment for cancer patients.”
The Qlucore Insights software, designed for research and enabling early testing and evaluation, is already available on the market. Currently, four models are being tested; two for different types of leukemia, one for lung cancer, and one for bladder cancer. Through these classification models, cancer types can be divided into several subgroups, leading to improved information.
Medtech4Health works to implement more medical technology ideas and solutions in healthcare for the benefit of patients. Through collaboration with healthcare providers, academia and the industry, value is created for patients and the medical technology sector is strengthened. Medtech4Health is funded by the Swedish government through the innovation agency Vinnova, the Swedish Energy Agency, the Swedish Research Council for Sustainable Development (Formas), and the programme's participating partners.
Visit: www.medtech4health.se
About Qlucore
Qlucore is a leading provider of new generation intuitive bioinformatics software for research and precision and companion diagnostics. Qlucore’s mission is to make it easier to analyse the huge amounts of complex data generated by innovations in the fields of genomics and proteomics by providing powerful visualisation-based bioinformatics data analysis tools for research and precision diagnostics. Qlucore Omics Explorer software is a easy to use bioinformatics software for research in the life science, plant- and biotech industries, as well as in academia. Qlucore Diagnostics and Qlucore Insights are software platforms with built in AI-based machine learning for multi-omics companion and precision diagnostics. Qlucore was founded in 2007 in Lund, Sweden and has customers in about 25 countries around the world, with sales offices in Europe and North America and distribution in several countries in Asia. Qlucore is listed on the Nasdaq First North Growth market.
Visit: www.qlucore.com
Innovations in Pharmaceutical Technology (IPT)
IPT provides a platform for cutting-edge ideas, concepts, and developments shaping the future of pharmaceutical R&D.